---
title: "GRI Bio, Inc. (GRI.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/GRI.US.md"
symbol: "GRI.US"
name: "GRI Bio, Inc."
industry: "Biotechnology"
---

# GRI Bio, Inc. (GRI.US)

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Location | US Market |
| Website | [www.gribio.com](https://www.gribio.com) |

## Company Profile

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natu...

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.30 | 115/604 | - | - | - |
| PB | 0.60 | 45/604 | 2.61 | 1.33 | 0.56 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2025-12-16T05:00:00.000Z

Total Analysts: **2**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 2 | 100% |
| Overweight | 0 | 0% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 261.80 |
| Highest Target | 6188.00 |
| Lowest Target | 4760.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/GRI.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/GRI.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/GRI.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.